EUVIMEDEUVIMED entdecken
Crossref

Intracavernosal injection of aviptadil and phentolamine for refractory erectile dysfunction

Abdullah Al-Mitwalli iD, Fiona Holden, Angelo Di Giovanni, Andrea Gobbo, Mohammad Shah, Giovanni Chiriaco, Pippa Sangster, David Ralph, Wai Gin Lee iD

The Journal of Sexual Medicine · 2025

DOI: 10.1093/jsxmed/qdaf067 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Sexual Medicine, 2025. Verfasst von Abdullah Al-Mitwalli und 8 weiteren Autor:innen. Beteiligte Einrichtung: University College London Hospital, Urology, London W1G 8PH, United Kingdom. Hauptthemen laut MEDLINE: Erectile Dysfunction, Phentolamine. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 19 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Intracavernosal injection (ICI), most commonly with alprostadil, is recommended for Phosphodiesterase 5 Inhibitors (PDE5i) nonresponders in erectile dysfunction (ED) treatment; however, its use can cause pain (12%) and priapism (1%).

Aim

We aimed to evaluate the efficacy of another ICI, Invicorp, and a combination of aviptadil with phentolamine mesylate (AvP), in contemporary practice.

Methods

We conducted a retrospective single-center analysis on patients referred for AvP because they developed intolerable Pain following Alprostadil ICI (group PA) or had Failed maximal dose (40 μg) of Alprostadil (group F). Self-administration was taught in a nurse-led clinic, followed by a 6-week telephone follow-up. Efficacy was evaluated at 3 months and was defined as resumption of penetrative sexual activity.

Results

Of these, 308 men were included in this study with a mean follow-up period of 13.3 months. All these patients had a trial of alprostadil ICI, 96% had failed PDE5i, 66% had trailed a vacuum erection device, and 36% had failed intraurethral alprostadil. Overall, 182 men (59%) found AvP ICI effective. Indications were 177 in the PA group and 131 in the FA group. Efficacy of AvP in the PA group was 76% and this compares to 36% in the FA group (P < .0001). The most common adverse event was facial flushing in 69 patients (22.5%). Ischemic priapism was reported in only one patient (0.3%). Clinical Implications AvP represents an effective and well-accepted second-line option for men who have experienced failure with most nonsurgical treatments for ED. Strengths and Limitations This is the largest and only study to outline the use of AvP ICI with clear distinguishing of efficacy rates for both patients who have failed conventional maximum dose alprostadil ICIs and those who developed pain from it. Limitations of this study include its retrospective design and lack of validated instruments to objectively assess erectile function.

Conclusion

Almost 60% of the participants with refractory ED were successfully managed through the administration of AvP.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Erectile DysfunctionPhentolamineHumansMaleRetrospective StudiesMiddle AgedAdultAlprostadilDrug Therapy, CombinationAgedTreatment OutcomePriapismInjectionsVasodilator Agents

Stichwörter der Autor:innen

Invicorpalprostadilerectile dysfunctionintracavernosal injectionphentolamine/aviptadil

Substanzen

PhentolamineAlprostadilVasodilator Agents

Autor:innen und Institutionen

  • University College London Hospital, Urology, London W1G 8PH, United Kingdom.
  • Division of Surgery and Interventional Sciences, University College London, London WC1E 6BT, United Kingdom.

ORCID-Profile: Abdullah Al-Mitwalli, Wai Gin Lee

Zitieren

APA

Al-Mitwalli, A., Holden, F., Di Giovanni, A., Gobbo, A., Shah, M., Chiriaco, G., Sangster, P., Ralph, D., & Lee, W. G. (2025). Intracavernosal injection of aviptadil and phentolamine for refractory erectile dysfunction. The Journal of Sexual Medicine. https://doi.org/10.1093/jsxmed/qdaf067

Vancouver

Al-Mitwalli A, Holden F, Di Giovanni A, Gobbo A, Shah M, Chiriaco G, et al. Intracavernosal injection of aviptadil and phentolamine for refractory erectile dysfunction. The Journal of Sexual Medicine. 2025. doi:10.1093/jsxmed/qdaf067

BibTeX
@article{AlMitwalli2025,
  author = {Al-Mitwalli, Abdullah and Holden, Fiona and Di Giovanni, Angelo and Gobbo, Andrea and Shah, Mohammad and Chiriaco, Giovanni and Sangster, Pippa and Ralph, David and Lee, Wai Gin},
  title = {Intracavernosal injection of aviptadil and phentolamine for refractory erectile dysfunction},
  journal = {The Journal of Sexual Medicine},
  year = {2025},
  doi = {10.1093/jsxmed/qdaf067}
}
Kostenlos starten →